Evidence map›Paper›PMID 32995122›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020

A Biomimetic Approach toward Enhancing Angiogenesis: Recombinantly Expressed Domain V of Human Perlecan Is a Bioactive Molecule That Promotes Angiogenesis and Vascularization of Implanted Biomaterials.

Xiaoting Lin, Fengying Tang, Shouyuan Jiang, Heba Khamis, Andre Bongers, John M Whitelock, Megan S Lord, Jelena Rnjak-Kovacina

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Proteoglycans and proteoglycan mimetics for tissue engineering.American journal of physiology. Cell physiology · 2022
    Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Xiaoting LinGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Fengying TangGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Shouyuan JiangGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Heba KhamisGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Andre BongersBiological Resources Imaging Laboratory University of New South Wales Sydney NSW 2052 Australia.
John M WhitelockGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Megan S LordGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.
Jelena Rnjak-KovacinaGraduate School of Biomedical Engineerin University of New South Wales Sydney NSW 2052 Australia.ORCID https://orcid.org/0000-0001-6121-4676
UNSW Sydney · AUUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenic therapy involving delivery of pro-angiogenic growth factors to stimulate new blood vessel formation in ischemic disease is promising but has seen limited clinical success due to issues associated with the need to deliver supra-physiological growth factor concentrations. Bio-inspired growth factor delivery utilizing the native growth factor signaling roles of the extracellular matrix proteoglycans has the potential to overcome many of the drawbacks of angiogenic therapy. In this study, the potential of the recombinantly expressed domain V (rDV) of human perlecan is investigated as a means of promoting growth factor signaling toward enhanced angiogenesis and vascularization of implanted biomaterials. rDV is found to promote angiogenesis in established in vitro and in vivo angiogenesis assays by potentiating endogenous growth factor signaling via its glycosaminoglycan chains. Further, rDV is found to potentiate fibroblast growth factor 2 (FGF2) signaling at low concentrations that in the absence of rDV are not biologically active. Finally, rDV immobilized on 3D porous silk fibroin biomaterials promotes enhanced vascular ingrowth and integration of the implanted scaffolds with the surrounding tissue. Together, these studies demonstrate the important role of this biologically active perlecan fragment and its potential in the treatment of ischemia in both native and bioengineered tissues.

Indexed as

angiogenesisbiomaterialsbiomimetic growth factorischemiaperlecansilkvascularization

Identifiers

PMID32995122
PMCPMC7507460
OpenAlexW3034881826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.